prophylactic group and 1000 TCID50 therapeutic group showed significant difference in the KC/GRO expression level on days 2 (p < 0.01) and 4 (p < 0.05) and day 3 (p < 0.05) after infection, respectively, compared to untreated control group (Figures 3(b)(i) and 3(b)(ii)). The gene discussed is CXCL1; the disease is infection.